
The FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated ALK-positive non-small cell lung cancer. In the ALKOVE-1 trial, 49% of patients previously treated with Alecensa (alectinib) responded. hubs.li/Q04FyX2j0
✓Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.

The FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated ALK-positive non-small cell lung cancer. In the ALKOVE-1 trial, 49% of patients previously treated with Alecensa (alectinib) responded. hubs.li/Q04FyX2j0

Two Extraordinary Healers, one message 💛 2025 finalist Kathleen Coughlin: “Nursing is not just what I do, it is who I am.” 2024 winner Meaghan Mooney: “Impact takes many forms.” Nominate an oncology nurse by Dec. 9 👉 hubs.li/Q04FqFSb0 #ExtraordinaryHealer #OncNurse

This Saturday: the Ruesch Center's Patient and Caregiver Day. Last chance to register! Register: hubs.li/Q04BzLHT0 @LombardiCancer @MedStarGUH @RueschCenter @Onclive #GICancer #CaregiverSupport

Wilserdly (giredestrant) plus everolimus is now FDA approved for ESR1-mutated advanced breast cancer, after a 62% lower risk of cancer growth or death in the evERA trial. hubs.li/Q04Fqxc70

🚩 Red flag or green flag? ✅ Former NFL linebacker and lung cancer advocate @chrisdraft weighs in on what helps (and what doesn't) when supporting someone through cancer care. Sometimes, the little things are the biggest green flags! 💚 #LungCancerAwarenessMonth

🚩 Red flag or green flag? ✅ Lung cancer advocate and former NFL linebacker @chrisdraft weighs in on what helps or hurts at diagnosis and in the care that follows. What’s one green flag you’ve seen in cancer care? 💬 #LungCancerAwarenessMonth

FDA approves perioperative durvalumab + enfortumab vedotin for cisplatin-ineligible MIBC. VOLGA vs cystectomy alone: - EFS HR 0.51 (median NR vs 12.1 mo) - OS HR 0.58 A new option for patients who can’t get cisplatin. #BladderCancer #OncX

Former NFL linebacker @chrisdraft honors his wife, LaKeasha, through lung cancer advocacy. He joined CURE® with a message for people living with lung cancer and their loved ones. 🤍 Stay tuned for more from Chris on CURE®! #LungCancerAwarenessMonth

Managing multiple myeloma means managing symptoms and treatment side effects, too. Join a free webinar by @themmrf where experts share practical strategies for both, plus how to talk with your care team. Wed, Nov 18 | 6:30 PM ET Register: hubs.li/Q04DXBzB0

FDA grants accelerated approval to Rybrevant Faspro for advanced head and neck cancer after chemo and immunotherapy. In the OrigAMI-4 trial, 42% of patients saw their tumors shrink or disappear. hubs.li/Q04DBs8c0

🎃 Carve out time for gratitude this Halloween. Nominate the oncology nurse who lit the way for you or your loved one for the 2027. Deadline: Dec. 9. hubs.li/Q04CVp5Z0 #ExtraordinaryHealer #OncologyNursing #Halloween #Gratitude

Living with or caring for someone with GI cancer? You’re not alone. Join @RueschCenter Nov 21 for Patient & Caregiver Day: survivorship, palliative care, and community. Register: hubs.li/Q04BxQrf0 @LombardiCancer @MedStarGUH @Onclive #GICancer #CaregiverSupport

FDA approves talazoparib + enzalutamide for metastatic hormone-sensitive prostate cancer with HRR gene mutations, based on TALAPRO-3 (rPFS HR 0.48; OS immature). Full story: hubs.li/Q04CkbMM0

FDA grants full approval to Keytruda for TMB-high solid tumors, but raises the cutoff to ≥13 mutations/megabase (from 10). In KEYNOTE-158, 36% of patients responded. What it means for patients: hubs.li/Q04C490d0

What does it mean to be “cured” of multiple myeloma? For the first time, experts have defined exactly that. Explore what this milestone means for patients in the latest issue of @themmrf Accelerator: hubs.li/Q04BxFMy0

Will you be in New Orleans? Make plans for an extraordinary evening! Join CURE® & @BloodCancerUtd on Dec. 11 for Extraordinary Honors in Blood Cancer, celebrating the people making a difference across the blood cancer community. 🎟️ Register: hubs.li/Q04BMmJz0